global health economics and outcomes research - school of pharmacy · 2020-02-20 · school of...
TRANSCRIPT
GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCHFELLOWSHIP PROGRAMUNIV OF WASHINGTON2017-2019
GHEOR Fellowship Program 2017-2019
PRODUCT VALUE PROPOSITION…outcomes research strategy based on product value, stakeholder needs & insights
VALUE COMMUNICATION …about evidence informing the value proposition to stakeholders
…informs health care decision making
EVIDENCE GENERATION AND TOOL DEVELOPMENT…through clinical and health economics & outcomes research (HEOR) data
Allergan plc (NYSE:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new
industry model - Growth Pharma. Our company is focused on developing, manufacturing and commercializing branded
pharmaceuticals, devices and biologic products for patients around the world. Allergan markets a portfolio of leading brands
and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology,
women’s health, urology, and anti-infective therapeutic categories. We are an industry leader in research and development,
with one of the broadest innovative development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline
programs in development. With commercial operations in approximately 100 countries, our company is committed to working
with physicians, healthcare providers and patients to deliver innovative and meaningful treatments to help people around the
world live longer, healthier lives. Learn more at www.Allergan.com.
ABOUT OUR COMPANY
OUR WORLD-CLASS MANUFACTURING AND R&D NETWORK
GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH (GHEOR) MISSION
GHEOR Fellowship Program 2017-2019
1
2
3
USAFall River, MA
Cincinnati, OH
Northern, CA (Biologics)
Irvine, CA (Biologics)
Waco, TX
Jersey City, NJ
Rockaway, NJ
Bridgewater, NJ
Irvine, CA
COSTA RICAHeredia, San Jose
BRAZILGuarulhos
IRELANDWestport
Clonshaugh, Dublin
Westport
BELGIUMLiege
GERMANYWeiterstadt
FRANCEPringy
Pringy
MANUFACTURING
CHINABeijing
Shanghai
JAPANTokyo
UKLiverpool
Marlow
R&D
SINGAPORESingapore
1
The University of Washington is a world-class leader in health sciences education and has been consistently listed in
US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly
noted for its strong research programs and since 1974 has received more federal funds for research and training
than any other public university in the United States. It fosters a highly collegial atmosphere between departments
and academic units, creating a particularly attractive environment for such partnerships between the public and
private sectors.
The Pharmaceutical Outcomes Research and Policy Program (PORPP) is housed within the University of Washington
School of Pharmacy, which boasts nearly 120 years of academic and research success. Faculty in the program (1)
provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs); (2)
conduct rigorous scientific research in the pharmacoeconomics and outcomes of pharmaceuticals and other health
technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with
the goal of improving patient care.
PORPP faculty participating in the fellowship have been chosen both for their dedication to teaching and their
excellence in research. Each is trained either as a health economist or health services researcher and all have an
extensive history of effective pharmacoeconomic and pharmacoepidemiologic research.
ABOUT OUR SCHOOL
GHEOR Fellowship Program 2017-2019 2
The University of Washington is a world-class leader in health sciences education and has been consistently listed in
US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly
noted for its strong research programs and since 1974 has received more federal funds for research and training
than any other public university in the United States. It fosters a highly collegial atmosphere between departments
and academic units, creating a particularly attractive environment for such partnerships between the public and
private sectors.
The Pharmaceutical Outcomes Research and Policy Program (PORPP) is housed within the University of Washington
School of Pharmacy, which boasts nearly 120 years of academic and research success. Faculty in the program (1)
provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs); (2)
conduct rigorous scientific research in the pharmacoeconomics and outcomes of pharmaceuticals and other health
technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with
the goal of improving patient care.
PORPP faculty participating in the fellowship have been chosen both for their dedication to teaching and their
excellence in research. Each is trained either as a health economist or health services researcher and all have an
extensive history of effective pharmacoeconomic and pharmacoepidemiologic research.
ABOUT OUR SCHOOL
GHEOR Fellowship Program 2017-2019 2
GHEOR Fellowship Program 2017-2019
UNIVERSITY OF WASHINGTON
Beth Devine, PharmD, MBA, PhD, FASHP
Associate Professor
Pharmaceutical Outcomes Research & Policy Program
1959 NE Pacifi c Avenue, H-375D
Box 357630
Seattle, WA 98195-7630
E-Mail: [email protected]
THE FELLOWSHIP PROGRAM Allergan and the University of Washington are pleased to off er two, 2-year GHEOR Fellowship positions for the academic year
2017-2019. Fellows will spend their fi rst year at the University of Washington (Seattle, WA), and the second year at Allergan
(Irvine, CA). The objective of the fi rst year is to educate fellows on the principles and methods used in health economics
and outcomes research. During the second year, fellows are provided with opportunities to gain practical knowledge and
experience with the use of clinical, economic, and humanistic data by supporting the development and commercialization of
pharmaceutical products. This will be accomplished by participating in work activities undertaken by the GHEOR team.
Compensation includes a competitive stipend, basic medical insurance, and holiday/vacation time. A Master’s (MS)
Degree is awarded upon completion of all course requirements and thesis project.
ALLERGAN PLC
Patrick Gillard, PharmD, MS
Director, GHEOR
2525 Dupont Drive
Irvine, CA 92612
E-Mail: [email protected]
Phone: (714) 246-2354
FELLOWSHIP DIRECTORS
ABOUT OUR FELLOWSHIPThe Allergan/University of Washington GHEOR Fellowship is a two-year program
that provides training and hands-on experience in a broad-range of health
economics and outcomes research topics. The program is structured to allow
fellows to gain profi ciency in health outcomes strategy and research as conducted
in both academic and pharmaceutical industry settings.
3
GHEOR Fellowship Program 2017-2019
FIRST YEAR OBJECTIVESThe objective of the fi rst year is to provide the fellow with the research tools necessary for pharmacoeconomic and
policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy,
and taught methods of economic assessment, health services research, epidemiology, clinical research design, and
biostatistical analyses.
The fellow will be assigned a MS thesis project which is selected based on input from both Allergan as well as the
University of Washington mentors. Fellows are highly encouraged to complete their MS project during their fi rst year.
Additionally, fellows will also engage in ongoing projects with Allergan throughout their fi rst year, applying skills from
previous pharmacy training as well as integrating new techniques developed from University of Washington courses.
Applying learning to solve real-world problems is a constant focus of the fellowship.
The fellow’s actual course of study will be developed on an individual basis with the Program Director, Dr. Beth Devine,
but will consist of courses in biostatistics, epidemiology, pharmacoeconomics and outcomes research, and health and
pharmaceutical policy.
AFTER COMPLETION OF THE FIRST-YEAR, THE FELLOW WILL HAVE A CLEAR UNDERSTANDING OF:• General principles of economics and in particular how economics infl uences the use, cost, and availability of
pharmaceuticals.
• The complex structure of drug policy and how it determines relationships between consumers, health care providers,
insurers, payers, and government agencies.
• The breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs),
economic modeling, retrospective database studies, and observational studies.
• Formulary development, maintenance and evaluation in institutional, managed care, and state-level
government programs.
1ST YEAR
FELLOWSHIP STRUCTURE
4
GHEOR Fellowship Program 2017-2019
SECOND YEAR OBJECTIVESThe second year of training will be at Allergan in Irvine, CA with the GHEOR department. This part of the program
is designed to allow the fellow to learn about the role of pharmacoeconomics and outcomes research in the drug
development and commercialization process within the industry setting. The research may be on an existing or
experimental product, for a disease state that is of interest to Allergan.
In addition to completing individual research project(s), fellows will participate in ongoing pharmacoeconomic
evaluations, outcomes research, and other projects in collaboration with the GHEOR team. These experiences will
provide the fellow with opportunities to interact with team members in other
departments at Allergan to learn how economic analyses and outcomes
research are used throughout the pharmaceutical industry. Fellows will
see fi rsthand how outcomes research is utilized to demonstrate the
place of Allergan products in treatment pathways and its value.
2ND YEAR
5
GHEOR Fellowship Program 2017-2019
UNIVERSITY OF WASHINGTON PROGRAM FACULTY
• Anirban Basu, PhD Professor and Stergachis Family Endowed
Director of PORPP
• Denise Boudreau, PhD Affi liate Associate Professor
• Beth Devine, PharmD, MBA, PhD, FASHP
Associate Professor, Director of Graduate
Programs
• Josh Carlson, MPH, PhD Associate Professor
• Louis P. Garrison, Jr., PhD Professor Emeritus
• Ryan Hansen, PhD, PharmD Assistant Professor
• Thomas K. Hazlet, PharmD, Dr. PH Associate Professor
• Scott D. Ramsey, MD, PhD Professor
• Sean D. Sullivan, PhD Professor and Dean of
School of Pharmacy
• David L. Veenstra, PharmD, PhD Professor and Associate Director of PORPP
Hema Viswanathan, BPharm, PhDDirector, GHEOR
Jonathan W. Kowalski, PharmD, MSVice President, US HEOR
Sepideh Varon, PhDSenior Director, GHEOR
Katelyn Keyloun, PharmD, MSPrincipal Research Associate, GHEOR
Vanessa Shih, PharmD, MSPrincipal Research Associate, GHEOR
Patrick Gillard, PharmD, MSDirector, GHEOR
Joanna Campbell, PhDDirector, GHEOR
ALLERGAN FELLOWSHIP MENTORS
Vaishali Patel, PharmD, MSSenior Director, GHEOR
• Joseph Babigumira Assistant Professor
• Aasthaa Bansal Research Assistant Professor
• Caroline Bennette Acting Assistant Professor
• Andy Stergachis Professor and Associate Dean for Research,
Graduate Programs and New Initiatives
6
GHEOR Fellowship Program 2017-2019
SHEILA SHAPOURI, PHARMDSheila joins the UW/Allergan fellowship after receiving her PharmD from the University of Washington in 2016.
Prior to pharmacy school, she worked as a research associate at the Allen Institute for Brain Science generating
publicly available neuroscience and genetics resources now used by researchers worldwide. Although she has
left the lab, her interest in improving health outcomes at a patient population level through targeted research
continues. During pharmacy school, Sheila completed clinical clerkships at the Food and Drug Administration
(FDA), PATH, and the Centers for Disease Control and Prevention (CDC). There she engaged in the application
of surveillance and outcomes data to guide healthcare decisions and policy at a national and global level.
Sheila participated in the AMCP P&T Competition and her team placed as semi-fi nalists nationally.
Sheila is looking forward to the opportunity to work with the PORPP faculty and Allergan team while gaining
the advanced training necessary to become an eff ective health economics and outcomes researcher. For her
thesis project, she will be building a predictive model for 30-day hospital readmissions or ER re-visits among
patients with acute bacterial skin and skin structure infections (ABSSSI).
MICHAEL SERBIN, PHARMDMichael received his PharmD degree from the University of Washington School of Pharmacy (UWSOP) in 2016
and a BS in biomedical engineering from the University of Southern California in 2011. At UWSOP he worked as
a research assistant and was recently published as a fi rst author in the Journal of Managed Care and Specialty
Pharmacy. Michael has interests in P&T decision-making, formulary development, and the application of
economic modeling. He focused his 4th year PharmD clerkships on formulary development and wrote P&T
submissions at Premera Blue Cross, UW Medical Center, and Providence Health. Michael competed in the
AMCP P&T competition where his team placed as semifi nalists nationally.
This year Michael is excited to start working with PORPP faculty and the GHEOR team at Allergan to improve
his research and economic modeling abilities. For his thesis project, Michael will use the Medical Expenditure
Panel Survey database to assess the societal burden of non-drop (surgery and other procedures) treatment of
glaucoma in patients unsuitable for drop therapy.
1ST YEAR FELLOWS
CURRENT FELLOWS
7
GHEOR Fellowship Program 2017-2019
SARAH BARADARAN, PHARMD, MSSarah received her doctorate of pharmacy from the University of Washington (UW) School of Pharmacy in 2015.
During the first year of her fellowship, she was involved in a pharmacogenomic evidence project with her
colleagues at UW, under mentorship from Professor Beth Devine. She also completed her thesis project entitled
"The identification and characterization of acute kidney injury (AKI) associated with systemic polymyxins in the
management of severe gram-negative infections."
During her second year of the fellowship, Sarah has worked in the infectious disease therapeutic area. She is
performing additional analyses to estimate the association between healthcare utilization, cost and acute kidney injury.
She will also begin supporting a project that will be an expansion of her thesis utilizing electronic health records. Sarah
is excited to apply her clinical and research skills on various projects throughout the second year of the fellowship.
ABSTRACTS FROM FELLOWSHIP:
1. Baradaran S, Keyloun K, Chin L, Pham J, Canestaro WJ, Devine B. Clinical evidence supporting
pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels: An update.
ISPOR 21st Annual International Meeting. Washington DC. May 2016 (Poster)
MANUSCRIPTS FROM FELLOWSHIP:
1. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in
FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. September 2016 (under review for
AMIA Joint Summits Meeting 2017)
AMY TUNG, PHARMD, MSAmy received her PharmD degree from the University of Washington (UW) in 2015. During the first year of her
fellowship, she completed her thesis titled “Characterizing Healthcare Utilization, Direct Costs, and Comorbidities
Associated with Interstitial Cystitis: A Retrospective Claims Analysis” under the mentorship of Professor Beth Devine.
During the second year of the fellowship, Amy has worked in the urology therapeutic area. After submitting her
thesis as a manuscript to the Journal of Managed Care Pharmacy, she has been analyzing data from a prospective
burden of illness study on nocturia to understand the association between frequency of nocturia episodes and
quality of life. In tandem, she is conducting a claims analysis to estimate the opioid burden in the interstitial cystitis
population as well as working with cross-functional departments to solicit feedback from global Health Technology
Assessment (HTA) experts on Allergan’s evidence synthesis and strategy plans for LiRIS®. Amy is excited to apply her
training in health economics and outcomes research in the industry setting during the second year of the fellowship.
ABSTRACTS FROM FELLOWSHIP:
1. Tung A, Hepp Z, Devine B. The Economic Burden of Interstitial Cystitis in the United States: A Literature
Review. UW Corporate Advisory Board Meeting. Seattle, WA. September 2015 (Poster)
2. Tung A, Hepp Z, Bansal A, Devine B. Characterizing Healthcare Utilization, Direct Costs, and Comorbidities
Associated with Interstitial Cystitis: A Retrospective Claims Analysis. ISPOR 21st Annual International
Meeting. Washington DC. May 2016 (Poster)
3. Luber K, Kawahara S, Wang D, Tung A, Burk C. The Quality of Life Among Women with Nocturia. American
Urogynecologic Society 37th Annual Scientific Meeting. Denver, CO. September 2016 (Poster)
MANUSCRIPTS FROM FELLOWSHIP:
1. Tung A, Hepp Z, Bansal A, Devine B. Characterizing Healthcare Utilization, Direct Costs, and Comorbidities
Associated with Interstitial Cystitis: A Retrospective Claims Analysis. ISPOR 21st Annual International
Meeting. Washington DC. August 2016 (under review at JMCP)
2ND YEAR FELLOWS
8
GHEOR Fellowship Program 2017-2019
Health Economist
Genentech, San Francisco, CA
MANUSCRIPTS FROM FELLOWSHIP1. Stewart Williams JA, Wallick CJ, Byles JE, Doran CM.Assessing patterns of use of cardio-protective polypill component
medicines in Australian women. Drugs Aging (2013)30:193-203
2. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and Health Care Resource Use Among
Commercially Insured Non-Elderly Patients With Diabetic Macular Edema. Ophthalmic surgery, lasers & imaging retina.
2015 Jul-Aug;46(7):744-51
3. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Cost of Diabetic Macular Edema in a Commercially
Insured Working Age Population (2013). (In Progress)
Principal Research Associate, Global Health Economics and Outcomes Research
Allergan plc, Irvine, CA
MANUSCRIPTS FROM FELLOWSHIP1. Shih V, Campbell J, Devine EB. The Association between Onset of Vision Impairment and Functional Limitations and
Informal Caregiving Requirements in Older Americans. (In Progress)
Pharmacy Quality, Utilization, and Clinical Programs Coordinator Group Health
Seattle, WA
MANUSCRIPTS FROM FELLOWSHIP 1. Yep T, Patel VD, Slejko JF, Devine EB. Comparing Total and Disease Related Healthcare Cost for Glaucoma Patients by
Disease Severity: A Retrospective Claims Database Analysis. (In Progress)
Principal Research Associate, Global Health Economics and Outcomes Research
Allergan plc, Irvine, CA
MANUSCRIPTS FROM FELLOWSHIP 1. Keyloun KR, Hansen R, Hepp Z, Gillard P, Thase M, Devine EB. Adherence and Persistence Across Antidepressant
Therapeutic Class: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
(Under review at CNS Drugs)
2. Mathias P, Hendrix N, Wang W, Keyloun KR, Khelifi M, Tarcyzy-Hornoch P, Devine EB. Characterizing pharmacogenomic-
guided medication use with a clinical data repository. (Under review at Clinical Pharmacology & Therapeutics)
3. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. September 2016 (under review for AMIA Joint Summits Meeting 2017)
PAST FELLOWSKATELYN
KEYLOUNPharmD, MS
2014-2016
VANESSA SHIH
PharmD, MS2014-2016
TRACY YEPPharmD, MS
2013-2015
CHRIS WALLICK
PharmD, MS2012-2014
9
GHEOR Fellowship Program 2017-2019
Associate Director
Abbvie, Chicago, IL
MANUSCRIPTS FROM FELLOWSHIP1. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among
patients with chronic migraine. Cephalalgia. 2015 May;35(6):478-88.
2. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in
improving medication safety in ambulatory care. Value Health. 2014 Jun;17(4):340-9
Research Scientist
Evidera, Seattle, WA
MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive
Bladder with Urinary Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence. BMC
Urology, 2009; 9(18)
Assistant Professor, UCSD Skaggs School of Pharmacy
San Diego, CA
MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder
with Urinary Urge Incontinence Refractory Oral Antimuscarinics. BMC Urology, 2009 Nov;20;9(18).
2. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for
Antimuscarinic Refractory Patients with Overactive Bladder. Urology, 2010 Oct;76(4):835-40.
3. Sand P, Rovner E, Dmochoswki R, Watanabe JH, Oefelein MG. Once-daily Trospium Chloride 60 mg Extended Release is
Safe and Effective in Subjects with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. Drugs
Aging, 2011 Feb;1;28(2):151-60
4. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr
Med Res Opin, 2011 May, 27(5):1041-8.
Director, Global Health Economics and Outcomes Research
Allergan plc, Irvine, CA
MANUSCRIPTS FROM FELLOWSHIP1. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from Disease- Specific Measures to Health-State Utility Values in
Individuals with Migraine. Value in Health 2012;15(3):485-94.
2. Doan QV, Brashear A, Gillard PJ, Varon SF, Turkel CC, Vandenburgh AM, Elovic EP. Relationship Between Disability Due to
Upper-Limb Post-Stroke Spasticity and Health-Related Quality of Life and Caregiver Burden, PM&R 2012;4(1):4-10.
Manager, Global Health Economics, Oncology
Amgen, Thousand Oaks, CA
MANUSCRIPTS FROM FELLOWSHIP1. Lin VW, Ringold S, Devine BE. Comparison of Ustekinumab with other Biologic Agents for Treatment of Moderate-to-
Severe Psoriasis: A Bayesian Network Meta-Analysis. Arch Dermatol. 2012 Dec;148(12):1403-10
2. Lin VW, Wright A, Flum DR, Alfonso RA, Garrison LP, Sullivan SD. Patients’ experience and outcomes after laparoscopic
adjustable gastric banding in Washington State. Surg Obes Relat Dis. 2013 Sep-Oct;9(5):701-5
3. Lin VW, Wong ES, Wright A. Association between health-related quality of life and body mass after adjustable gastric
banding: a nonlinear approach. Value in Health. 2013 Jul;16(5):823-9
Consultant, Health Economics and Outcomes Research
Seattle, WA
MANUSCRIPTS FROM FELLOWSHIP1. JC Sanderson, EB Devine, RB Lipton, LM Bloudek, SF Varon, AM Blumenfeld, PJ Goadsby, DC Buse, SD Sullivan. Headache-
related health resource utilization in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry.
2013 Dec;84(12):1309-17
2. Messali A, Sanderson JC, Blumenfeld AM. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States:
A Web-Based Survey. Headache. 2016 Feb;56(2):306-22
JONATHAN H. WATANABE
PharmD, MS, PhD2007-2009
ZSOLT HEPPPharmD, MS
2012-2014
JOANNA SANDERSON
PharmD, MS2011-2013
VINCENT W. LIN
PharmD, MS2010-2012
PATRICK GILLARD
PharmD, MS2009-2010
KATHARINE S. GRIES
PharmD, MS, PHD2008-2010
10
NYSE:AGN | www.Allergan.com
© 2016 Allergan. ® Marks owned by Allergan. All rights reserved
APPLICATION INFORMATION Interested students must apply to both the University of Washington Graduate School, as well as the Pharmaceutical
Outcomes Research & Policy Program. The online application process can be found at:
http://sop.washington.edu/department-of-pharmacy/pharmaceutical-outcomes-research-policy-program-
porpp/fellowship-opportunities/
CONTACT INFORMATIONIf you have any questions, please contact:
UNIVERSITY OF WASHINGTON
Penny Evans
Graduate Program Advisor
Box 357630
University of Washington
Seattle, WA 98195-7630
E-Mail: [email protected]
Phone: (206) 616-1383
Fax: (206) 543-3835
DEADLINE The application deadline is
December 15, 2016
and the start date of the
Fellowship is July 1, 2017
ALLERGAN PLC
Patrick Gillard, PharmD, MS
Director, GHEOR
2525 Dupont Drive
Irvine, CA 92612
E-Mail: [email protected]
Phone: (714) 246-2354
Applicants for this fellowship must have a degree in pharmacy or health-related
discipline and have some research experience (preference will be given to those with
a high academic standing). Excellent written and verbal communication skills are also
essential. Applicants will be required to submit their curriculum vitae, a letter
describing their career goals, and three letters of recommendation.
Selection of fellows will be made by a steering committee
composed of the University of Washington faculty
members and representatives from Allergan.
APPLICATION ELIGIBILITY